NR3C2 and Gynecomastia: Finerenone is a non‐steroidal, selective MRA with greater mineralocorticoid receptor affinity and selectivity, and as such its use is associated with less hyperkalaemia and minimal gynaecomastia compared with the steroidal MRAs.42